Oncorad Group, a Moroccan oncology center, has achieved a milestone with the publication of a study in a US medical journal on the use of 3D-printed personalized brachytherapy for penile cancer. This marks the first Moroccan contribution to international scientific literature on this technique, which aims to preserve the organ in affected patients.
The study, published in Brachytherapy (the official journal of the American Brachytherapy Society) on June 18, 2026, details a case of a patient with squamous cell carcinoma of the glans penis. The treatment involved a custom 3D-printed applicator designed to deliver high-dose-rate brachytherapy precisely to the tumor while sparing healthy tissue.
According to the research team led by Dr. Khalid El Bouihi, the patient achieved complete remission at 12 months follow-up with no local recurrence and preserved organ function. The technique offers an alternative to partial or total penectomy, which can have significant psychological and functional impacts.
This advancement is part of a broader trend in Morocco toward integrating 3D printing in radiotherapy, with Oncorad Group having previously used similar approaches for other cancers. The study was funded by the Moroccan Ministry of Health and the Hassan II Academy of Science and Technology.
